AstraZeneca’s Truqap flops in phase III triple-negative breast cancer trial

cafead

Administrator
Staff member
  • cafead   Jun 18, 2024 at 12:02: PM
via Bucking its recent winning streak in oncology, AstraZeneca reported Tuesday that its AKT inhibitor Truqap failed to significantly boost overall survival in patients with triple-negative breast cancer.

article source
 

<